New name and reorganisation for Bayer Schering Pharma's healthcare arm in France
As the reorganisation of the recently formed pharmaceuticals giant Bayer Schering Pharma continues, the Bayer HealthCare division plans to close its Puteaux (Paris) facility and relocate staff to a new building being built at the Eurosante biotech business park in Lille.
As the reorganisation of the recently formed pharmaceuticals giant Bayer Schering Pharma continues, the Bayer HealthCare division plans to close its Puteaux (Paris) facility and relocate staff to a new building being built at the Eurosante biotech business park in Lille.
Work will start on the new 6,000m2 facility in October and the move may involve as many as 350 employees mainly in administration, support and marketing.
Headquartered in Berlin, Bayer HealthCare has also renamed its French division Bayer Sante but it will carry the same Bayer HealthCare logo. The company will keep its existing French r&d facility in Lille and will have office space for 400 administration and support staff at the new facility by March 2008.
Olivier Ertzbischoff, medical director, said the healthcare division was increasing its r&d capability and plans to focus future research on oncology, cardiology, haematology and women's healthcare. It currently invests 15-17% of total net sales in r&d.
The company hopes to accelerate the penetration of its anti-cancer drug Nexavar and further exploit its oncology pipeline. It is adding new benefits to its Yaz line of contraceptives and developing new cardiovascular and DVT drugs. Currently working on new treatments for multiple sclerosis and Parkinson's disease, the company aims to be a leader in these fields too.